ArticlePigment cell & melanoma research2009
NRG1 / ERBB3 signaling in melanocyte development and melanoma: inhibition of differentiation and promotion of proliferation.
Article in Pigment cell & melanoma research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 82 citations in OpenAlex.
- An Itch Receptor Drives Melanoma.bioRxiv : the preprint server for biology · 2026Article
- Primary Jejunal Melanoma Presenting as Widespread Metastases: Clinicopathological and Embryological Perspectives-A Case Report.Case reports in surgery · 2026Article
- Article
- Pannexin 1 crosstalk with the Hippo pathway in malignant melanoma.The FEBS journal · 2025Article
- Pannexin 1 crosstalk with the Hippo pathway in malignant melanoma.bioRxiv : the preprint server for biology · 2024Article
- Study on the relationship between Methylation of Neuregulin (NRG) Gene and Cervical Carcinoma.Pakistan journal of medical sciences · 2024Article
- Genome-Wide Association Analysis Identifies theAnimals : an open access journal from MDPI · 2023Article
- Generation of Schwann cell derived melanocytes from hPSCs identifies pro-metastatic factors in melanoma.bioRxiv : the preprint server for biology · 2023Article
- Human epidermal growth factor receptor 3 serves as a novel therapeutic target for acral melanoma.Cell death discovery · 2023Article
- Canonical Wnt and TGF-β/BMP signaling enhance melanocyte regeneration but suppress invasiveness, migration, and proliferation of melanoma cells.Frontiers in cell and developmental biology · 2023Article
- Endogenous DOPA inhibits melanoma through suppression of CHRM1 signaling.Science advances · 2022Article
- Genetic Connections and Convergent Evolution of Tropical Indigenous Peoples in Asia.Molecular biology and evolution · 2022Article
- Genetic alteration of Chinese patients with rectal mucosal melanoma.BMC cancer · 2021Article
- Xmrks the Spot: Fish Models for Investigating Epidermal Growth Factor Receptor Signaling in Cancer Research.Cells · 2021Review
- miR-17-5p and miR-20a-5p suppress postoperative metastasis of hepatocellular carcinoma via blocking HGF/ERBB3-NF-κB positive feedback loop.Theranostics · 2020Article
- RNA-seq and microRNA-seq analysis of Japanese flounder (Paralichthys olivaceus) larvae treated by thyroid hormones.Fish physiology and biochemistry · 2019Article
- Neuregulin-1 is essential for nerve plexus formation during cardiac maturation.Journal of cellular and molecular medicine · 2018Article
- Afatinib reverses ceritinib resistance (CR) in ALK/ROS1-positive non-small-cell lung cancer cell (NSCLC) via suppression of NRG1 pathway.OncoTargets and therapy · 2018Article
- An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.Journal of the National Cancer Institute · 2017Article
- Tanapoxvirus lacking a neuregulin-like gene regresses human melanoma tumors in nude mice.Virus genes · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
Neuregulin (NRG) signaling through the receptor tyrosine kinase, ERBB3, is required for embryonic development, and dysregulated signaling has been associated with cancer progression. Here, we show that NRG1/ERBB3 signaling inhibits melanocyte (MC) maturation and promotes undifferentiated, migratory and proliferative cellular characteristics. Embryonic analyses demonstrated that initial MC specification and distribution were not dependent on ERBB3 signaling. However NRG1/ERBB3 signaling was both necessary and sufficient to inhibit differentiation of later stages of MC development in culture. Analysis of tissue arrays of human melanoma samples suggests that ERBB3 signaling may also contribute to metastatic progression of melanoma as ERBB3 was phosphorylated in primary tumors compared with nevi or metastatic lesions. Neuregulin 1-treated MCs demonstrated increased proliferation and invasion and altered morphology concomitant with decreased levels of differentiation genes, increased levels of proliferation genes and altered levels of melanoma progression and metastases genes. ERBB3 activation in primary melanomas suggests that NRG1/ERBB3 signaling may contribute to the progression of melanoma from benign nevi to malignancies. We propose that targeting ERBB3 activation and downstream genes identified in this study may provide novel therapeutic interventions for malignant melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.